Thanks for the update Kelsee. Just a reminder of the "current" trial design. After initial screening, there is a 1-2 week atorvastatin or rosuvastatin run-in period, followed by randomization and apabetalone/placebo treatment duration up to 104 weeks, followed by a 4-16 week safety follow up period.

The November 11, 2015 news release stated "Resverlogix Corp. (the "Corporation") (TSX:RVX) today announced that the first patient has been randomized and dosing has commenced in the Phase 3 clinical trial 'BETonMACE' with lead drug apabetalone (RVX-208) in high-risk patients with coronary artery disease (CAD) and type 2 diabetes mellitus (DM)."

If indeed November 11, 2015 was start of apabetalone/placebo dosing for the first patient(s), then these first patient(s) will complete their 104 week dosing on November 11, 2017 and start the 4-16 week safety follow up period. In other words, these patients that reach 104 week dosing will not longer be eligible to contribute to the MACE event tally, if they haven't already had a first 3-point MACE event, as they are going off drug after 104 weeks. 

BearDownAZ